Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
AstraZeneca
Mallinckrodt
Johnson and Johnson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ENMD-1198

See Plans and Pricing

« Back to Dashboard

What is the drug development status for ENMD-1198?

ENMD-1198 is an investigational drug.

There have been 8 clinical trials for ENMD-1198. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are CASI Pharmaceuticals, Inc., University Health Network, Toronto, and University of Colorado, Denver.

There are two US patents protecting this investigational drug and six international patents.

Recent Clinical Trials for ENMD-1198
TitleSponsorPhase
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaCASI Pharmaceuticals, Inc.Phase 2
A Study of ENMD-2076 in Ovarian Clear Cell CancersUniversity Health Network, TorontoPhase 2
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue SarcomaUniversity Health Network, TorontoPhase 2

See all ENMD-1198 clinical trials

Clinical Trial Summary for ENMD-1198

Top disease conditions for ENMD-1198
Top clinical trial sponsors for ENMD-1198

See all ENMD-1198 clinical trials

US Patents for ENMD-1198

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ENMD-1198   Start Trial Antiangiogenic agents EntreMed, Inc. (Rockville, MD)   Start Trial
ENMD-1198   Start Trial Methods of treating disease states using antiangiogenic agents EntreMed, Inc. (Rockville, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ENMD-1198

Drugname Country Document Number Estimated Expiration Related US Patent
ENMD-1198 Australia 2005222934 2024-03-12   Start Trial
ENMD-1198 Canada 2558014 2024-03-12   Start Trial
ENMD-1198 European Patent Office 1756139 2024-03-12   Start Trial
ENMD-1198 Japan 2007529426 2024-03-12   Start Trial
ENMD-1198 World Intellectual Property Organization (WIPO) 2005089256 2024-03-12   Start Trial
ENMD-1198 World Intellectual Property Organization (WIPO) 2008011005 2024-03-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Express Scripts
Mallinckrodt
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.